138 related articles for article (PubMed ID: 37075941)
1. Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock.
Metra M; Chioncel O; Davison B; Filippatos G; Mebazaa A; Pagnesi M; Adamo M; Novosadova M; Ponikowski P; Simmons P; Soffer J; Simonson S; Cotter G
J Card Fail; 2023 Jul; 29(7):1097-1103. PubMed ID: 37075941
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Metra M; Chioncel O; Cotter G; Davison B; Filippatos G; Mebazaa A; Novosadova M; Ponikowski P; Simmons P; Soffer J; Simonson S
Eur J Heart Fail; 2022 Oct; 24(10):1967-1977. PubMed ID: 35867804
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
[TBL] [Abstract][Full Text] [Related]
4. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
Carubelli V; Zhang Y; Metra M; Lombardi C; Felker GM; Filippatos G; O'Connor CM; Teerlink JR; Simmons P; Segal R; Malfatto G; La Rovere MT; Li D; Han X; Yuan Z; Yao Y; Li B; Lau LF; Bianchi G; Zhang J;
Eur J Heart Fail; 2020 Sep; 22(9):1684-1693. PubMed ID: 31975496
[TBL] [Abstract][Full Text] [Related]
5. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
8. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
9. Istaroxime: a new luso-inotropic agent for heart failure.
Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
[TBL] [Abstract][Full Text] [Related]
10. SERCA2a Agonist Effects on Cardiac Performance During Exercise in Heart Failure With Preserved Ejection Fraction.
Sarma S; MacNamara JP; Hieda M; Howden EJ; Lawley JS; Livingston S; Samels M; Levine BD
JACC Heart Fail; 2023 Jul; 11(7):760-771. PubMed ID: 37086245
[TBL] [Abstract][Full Text] [Related]
11. Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.
Arici M; Ferrandi M; Barassi P; Hsu SC; Torre E; Luraghi A; Ronchi C; Chang GJ; Peri F; Ferrari P; Bianchi G; Rocchetti M; Zaza A
J Pharmacol Exp Ther; 2023 Jan; 384(1):231-244. PubMed ID: 36153005
[TBL] [Abstract][Full Text] [Related]
12. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
13. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
[TBL] [Abstract][Full Text] [Related]
14. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV
Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771
[TBL] [Abstract][Full Text] [Related]
15. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
Torre E; Arici M; Lodrini AM; Ferrandi M; Barassi P; Hsu SC; Chang GJ; Boz E; Sala E; Vagni S; Altomare C; Mostacciuolo G; Bussadori C; Ferrari P; Bianchi G; Rocchetti M
Cardiovasc Res; 2022 Mar; 118(4):1020-1032. PubMed ID: 33792692
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Istaroxime in Patients With Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
Khalid Khan S; Rawat A; Khan Z; Reyaz I; Kumar V; Batool S; Yadav R; Hirani S
Cureus; 2023 Jun; 15(6):e41084. PubMed ID: 37519574
[TBL] [Abstract][Full Text] [Related]
17. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
18. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
[TBL] [Abstract][Full Text] [Related]
19. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
[TBL] [Abstract][Full Text] [Related]
20. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
